NEW YORK — U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause ...
In a 15-0 vote, ACIP recommended that MenB-4C be administered as a two-dose series at 0 and 6 months when given to healthy ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines.
The committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.
The company will use the funds to advance its pipeline of cancer-targeting preclinical candidates to the “clinic-ready” stage ...
Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 14–1 in favor of expanding the agency’s guidance for ...
Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback